Trial Condition(s):

Hypertension

High Dose BAYA1040_Nifedipine: a long term combination study

Bayer Identifier:

14024

ClinicalTrials.gov Identifier:

NCT01294215

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at target blood pressure by the combination of BAYA1040_Nifedipine 40 mg once daily and other antihypertensives.

Inclusion Criteria
- 20 years or older
 - Japanese male or female
 - Outpatient with essential hypertension
 - Patients who are treated with Adalat CR 40 mg od and at least one antihypertensive drug (other than Ca antagonists) for 4 weeks or more before entry in this study
Exclusion Criteria
- Patients whose sitting diastolic blood pressure (DBP) is 110 mm Hg or more
 - Patients with secondary hypertension or hypertensive emergency

Trial Summary

Enrollment Goal
72
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Adalat CC (Nifedipine, BAYA1040)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Sugiura Iin

Kawaguchi, Japan, 332-0012

Status
Completed
 
Locations

Sagamino Central Hospital

Ebina, Japan, 243-0401

Status
Completed
 
Locations

Oda Clinic

Shinjuku, Japan, 169-0072

Status
Completed
 
Locations

Yamamoto Clinic

Sagamihara, Japan, 252-0311

Status
Completed
 

Trial Design